See also this year's filing and all EDGAR filings for this company.
PDF Report 0001566044_2023_VYNE_Therapeutics_Inc.pdf
Logs
Graph
Absolute values for 0001566044, VYNE Therapeutics Inc
| xvar | xval | |
|---|---|---|
| 0 | AssetsCurrent | 38,275,000 |
| 1 | IntangibleAssetsNetIncludingGoodwill | 0 |
| 2 | PropertyPlantAndEquipmentNet | 0 |
| 3 | remainder_Assets | 2,483,000 |
| 4 | LiabilitiesCurrent | 0 |
| 5 | LiabilitiesNoncurrent | 0 |
| 6 | remainder_Liabilities | 9,345,000 |
| 7 | CostOfGoodsAndServicesSold | 1,507,916 |
| 8 | SellingGeneralAndAdministrativeExpense | 17,734,810 |
| 9 | ResearchAndDevelopmentExpense | 10,876,741 |
| 10 | remainder_Expenses | 1,729,820 |
| 11 | remainder_Revenues | 5,680,174 |
| 12 | remainder_NetIncome | 11,165,972 |
| 13 | remainder_ComprehensiveNetIncome | 0 |
| yvar | yval | |
|---|---|---|
| 0 | Assets | 40,758,000 |
| 1 | Liabilities | 9,345,000 |
| 2 | Expenses | 31,849,287 |
| 3 | Revenues | 5,680,174 |
| 4 | StockholdersEquity | 31,413,000 |
| 5 | NetIncome | -15,003,141 |
| 6 | ComprehensiveNetIncome | -15,003,141 |
| 7 | BaseVar | 49,399,216 |
| 8 | EconomicCapitalRatiobeforeLimitedLiability | 2.13 |
| 9 | EconomicCapitalRatio | 3.11 |
Edgar->Model Mapping
Feature Distribution
Change over Time
